Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Meningococcal conjugate vaccines are today successfully deployed in universal programs for children and adolescents in different geographic regions to control meningitis and septicemia. However, in adults, the advantages of these conjugates over the older polysaccharide vaccines are less clear. In this randomized clinical trial, we demonstrated that both conjugate and polysaccharide quadrivalent meningococcal vaccines elicit protective antibody responses in adults aged 18 to 70. (This study has been registered at www.clinicaltrials.gov under registration no. NCT00901940.).

Original publication

DOI

10.1128/CVI.00099-14

Type

Journal article

Journal

Clin Vaccine Immunol

Publication Date

08/2014

Volume

21

Pages

1164 - 1168

Keywords

Adult, Aged, Antibodies, Bacterial, Antigens, Bacterial, Female, Humans, Male, Meningitis, Meningococcal, Meningococcal Vaccines, Middle Aged, Neisseria meningitidis, Polysaccharides, Bacterial, United Kingdom, Vaccination, Vaccines, Conjugate, Young Adult